等待开盘 04-03 09:30:00 美东时间
+0.540
+2.17%
今日重点评级关注:HC Wainwright & Co.:维持OCUGEN"买入"评级,目标价从7美元升至10美元;HC Wainwright & Co.:维持Maze Therapeutics"买入"评级,目标价从60美元升至110美元
03-26 11:41
Morgan Stanley analyst Robert Kad maintains WaterBridge Infr (NYSE:WBI) with a Equal-Weight and raises the price target from $32 to $34.
03-26 01:46
今日重点评级关注:花旗:维持Candel Therapeutics"买入"评级,目标价从22美元升至26美元;Chardan Capital:维持CervoMed"买入"评级,目标价从15美元升至21美元
03-19 14:31
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据WaterBridge Infrastructure LLC业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** - 2025年全年备考营收7.90亿美元,同比增长19% - 第四季度营收2.089亿美元,环比增长2% **盈利能力:** - 2025年全年调整后EBITDA为4.028亿美元,同比增长16% - 第四季度调整后EBITDA为1.038亿美元,EBITDA利润率达50% - 2025年全年备考净亏损5,810万美元 - 第四季度净亏损1,360万美元 **运营指标:** - 产出水处理量全年平均240万桶
03-17 12:21
Waterbridge Infrastructure LLC Class A (($WBI)) has held its Q4 earnings call. ...
03-17 08:10
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
WaterBridge Infr (NYSE:WBI) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $0.05 by 266.67 percent. The company reported quarterly sales of $208.881 million which beat the
03-16 18:19
今日重点评级关注:Piper Sandler:维持Allogene疗法"超配"评级,目标价从7美元升至8美元;B. Riley证券:维持Oncology Institute"买入"评级,目标价从6美元升至8美元
03-16 18:19
Wells Fargo analyst Praneeth Satish maintains WaterBridge Infr (NYSE:WBI) with a Equal-Weight and raises the price target from $25 to $26.
03-13 22:57
今日重点评级关注:HC Wainwright & Co.:维持Assertio Holdings"买入"评级,目标价从3美元升至35美元;HC Wainwright & Co.:维持万达生物制药"买入"评级,目标价从20美元升至22美元
01-06 17:52